RxDoctor Payments Data

Greyson Thomas, MD

Internal Medicine · Fort Mc Coy, FLNPI 1467682104

Payments from drug & device makers

$7,249in general payments, 2019–2025

Across 442 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$964
  • Boehringer Ingelheim$813
  • Novo Nordisk$748
  • Sanofi-aventis U.S. LLC$562
  • Lilly USA, LLC$360
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$7,222100%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,249 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$62,151
Medicare patients
166
Services billed
797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol128$144,770
EliquisApixaban70$98,970
JardianceEmpagliflozin52$77,664
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$69,159
OzempicSemaglutide25$42,821
TrulicityDulaglutide21$34,700
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr37$33,364
XareltoRivaroxaban20$31,883
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$29,984
MounjaroTirzepatide21$28,548
Spiriva RespimatTiotropium Bromide23$28,040
JanuviaSitagliptin Phosphate21$23,692
VraylarCariprazine Hcl14$23,278
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$15,761
SymbicortBudesonide/Formoterol Fumarate22$11,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$964$186,149171 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$813$121,46589 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,696$102,524100 claims
PfizerEliquis$345$98,97070 claims
Lilly USA, LLCTrulicity, Mounjaro$360$63,24842 claims
Novo NordiskOzempic$748$42,82125 claims
Johnson & JohnsonXarelto$338$31,88320 claims
AbbVieVraylar, Synthroid$73$25,10837 claims
MerckJanuvia$263$23,69221 claims
Sanofi-aventis U.S. LLCLantus$562$2,07412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Fort Mc Coy

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →